索拉非尼治疗晚期肾癌患者的总体生存期分析

Overall survival of Sorafenib treatment for patients with advanced kidney cancer

目的：通过分析13例服用索拉非尼患者的生存期，探讨索拉非尼在延长晚期肾癌患者的总体生存期的临床治疗经验。方法回顾2004年1月至2013年10月我院晚期转移性肾癌患者13例的临床资料，男9例，女4例；年龄37～75岁，中位年龄53岁。13例患者中保守治疗2例，行肾癌根治术11例。用药方法为连续口服索拉非尼400mg或600mg，2次／d。观察患者的总体生存期、中位生存期、中位无疾病进展时间和不良反应发生率。结果13例服药患者中，肺肿瘤转移灶体积缩小≥30％4例（30．7％），＜30％5例（38．5％），肺转移灶缩小3个月后开始增大，但未超过20％或出现新病灶4例（30．7％）。常见不良反应包括手足皮肤病变、腹泻、高血压、乏力，对症治疗后大多数可缓解，无需停药。结论索拉非尼能够抑制晚期肾癌的进展，延长患者的总体生存期。

Objective To explore the clinical treatment experience of Sorafenib in prolonging the overall survival of pa‐tients with advanced kidney cancer .Methods Clinical data of 13 cases of advanced kidney cancer treated during Jan .2004 and Oct .2013 were retrospectively reviewed .The patients included 9 males and 4 females ,aged 37‐75 years ,the median age being 53 years .Of all patients ,2 received conservative treatment and 11 underwent radical treatment .Sorafenib 400 mg or 600 mg was given twice per day .The patients＆#39;overall survival ,median survival period ,median time of disease progression and inci‐dence of adverse reactions were observed .Results Of all 13 cases ,4 （30 .7% ） had lung tumor metastases shrinkage ≥ 30% , 5 （38 .5） had lung metastases shrinkage 〈30% .In another 4 cases （30 .7% ） ,lung metastases began to enlarge after 3 months , but the enlargement was 〈20% and no new lesions occurred .Common adverse reactions included foot and skin lesions ,diar‐rhea ,high blood pressure and fatigue ,most of which could alleviate after symptomatic treatment .There was no need not stop Sorafenib medication .Conclusion Sorafenib can inhibit the progress of advanced kidney cancer and prolong the overall sur‐vival of patients .